"Not So Different": The Year in US Regulatory Activity for Biosimilars

When it comes to US biosimilars, 2019 was a busy year for regulatory activity. This week on the podcast, we're rounding up the key developments of the year.

Related Content:

PodcastsRegulatory

Biosimilars Regulatory Roundup: May 2025

Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships

FDA Approves Starjemza as New Stelara Biosimilar